HB3355 updates the statutory language governing the Oklahoma Medical Marijuana Authority (OMMA) and the Oklahoma Medical Marijuana and Patient Protection Act. The bill restates and reorganizes the Authority’s role in administering the state’s medical marijuana program, including patient and business licensing, regulation of cultivation, processing, testing, transport, storage, research, and sale of medical marijuana. It also preserves the Authority’s existing powers to enforce the program through investigations, fines, subpoenas, inspections, injunctions, and rulemaking.
A major structural change in the bill is that, beginning on the effective date, OMMA would cease to be part of the State Department of Health and would instead operate as a separate and distinct state agency. The bill provides for the transfer of records, property, funds, liabilities, contracts, and other assets from the Department to the Authority, and it preserves the rights and privileges of existing licenses. It also addresses the transfer of personnel, requiring employee consent for transfers and protecting salary, leave, and retirement-related benefits for employees who move to the new agency. The bill further directs OMMA to continue implementing the voter-approved medical marijuana framework consistent with State Question 788 and related law.
The bill also expands or clarifies several administrative functions of OMMA. These include developing best practices for marijuana research, contracting with vendors and other agencies, establishing internal controls and fee schedules, collecting information from licensees to prevent diversion, and coordinating with other state agencies on enforcement. It also authorizes OMMA to declare a moratorium on new business licenses for a period it deems necessary and to work with banking and treasury officials on financial best practices if federal law changes.
Overall, the available context suggests a neutral to favorable administrative sentiment, with the bill presented as an update to existing law rather than a major policy shift. There are no recorded committee transcripts or votes in the provided materials, so there is no direct evidence of debate or opposition in the record supplied. The bill’s caption and text emphasize updating language and clarifying agency structure and authority, indicating a technical and organizational measure focused on program administration.
The main point of potential contention is the bill’s consolidation of authority and its explicit separation of OMMA from the Department of Health, which could affect agency oversight, staffing, and enforcement discretion. Another possible issue is the broad authority given to OMMA to impose a moratorium on new licenses and to require extensive business information, which may concern license holders or industry participants. However, no specific opposition or support is documented in the provided legislative history.
HB3355 would amend 63 O.S. Section 427.3, the core statute establishing the Oklahoma Medical Marijuana Authority, by changing OMMA’s status from a division within the State Department of Health to an independent state agency and by updating the agency’s powers, duties, and transition provisions. It would affect the administration of the Oklahoma Medical Marijuana and Patient Protection Act, existing medical marijuana licenses, agency personnel, records, assets, liabilities, and enforcement procedures. The bill would primarily impact OMMA, the Department of Health, licensed medical marijuana businesses, patients, and related state enforcement and financial agencies.
The bill appears to have a generally administrative and noncontroversial tone in the materials provided, with no recorded committee debate or votes to indicate strong support or opposition. Its language suggests an effort to modernize and clarify the structure of the medical marijuana regulatory system rather than to change the underlying policy direction. Because no transcripts or vote history are included, the public or legislative sentiment can only be characterized as neutral based on the bill text itself.
The most notable areas of possible contention are the bill’s reorganization of OMMA into a separate agency, which may raise questions about oversight, staffing, and administrative control, and its broad regulatory powers, including the ability to suspend new business licenses through a moratorium and to require detailed operational information from licensees. Medical marijuana businesses could view these provisions as increasing regulatory burden or uncertainty, while state regulators may see them as necessary tools for enforcement and diversion prevention. No specific objections or supporters are identified in the provided record.